



Date: May 3, 2024

Via Email: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637

To Whom it May Concern:

Day One Biopharmaceuticals, Inc. submits this information pursuant to 18 V.S.A. § 4637(b). On May 7, 2024, Day One Biopharmaceuticals, Inc. will release the following Prescription drug to the commercial market:

NDC	Drug Description	WAC
82950-0001-16	ojemda (tovorafenib) 100mg Tablets, 16 Count	\$ 33,916.00
82950-0001-20	ojemda (tovorafenib) 100mg Tablets, 20 Count	\$ 33,916.00
82950-0001-24	ojemda (tovorafenib) 100mg Tablets, 24 Count	\$ 33,916.00
82950-0012-01	ojemda (tovorafenib) (oral suspension) 300mg/12ml	\$ 8,479.00

Day One Biopharmaceuticals, Inc. provides this notice consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions.

Thank you for your consideration.

Sincerely,

**Marcus Farbstein, RPh**

Director, Pricing & Contracting

Mobile: +1 703.662.1852

[Marcus.Farbstein@DayOneBio.com](mailto:Marcus.Farbstein@DayOneBio.com)

[www.DayOneBio.com](http://www.DayOneBio.com)